JP2015509539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509539A5 JP2015509539A5 JP2014561067A JP2014561067A JP2015509539A5 JP 2015509539 A5 JP2015509539 A5 JP 2015509539A5 JP 2014561067 A JP2014561067 A JP 2014561067A JP 2014561067 A JP2014561067 A JP 2014561067A JP 2015509539 A5 JP2015509539 A5 JP 2015509539A5
- Authority
- JP
- Japan
- Prior art keywords
- solid preparation
- weight
- core
- preparation according
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims 21
- 238000002360 preparation method Methods 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 7
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 6
- 229960004963 mesalazine Drugs 0.000 claims 6
- 239000003826 tablet Substances 0.000 claims 6
- 239000011248 coating agent Substances 0.000 claims 5
- 238000000576 coating method Methods 0.000 claims 5
- 239000001856 Ethyl cellulose Substances 0.000 claims 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 4
- 229920001249 ethyl cellulose Polymers 0.000 claims 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000010687 lubricating oil Substances 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000001069 triethyl citrate Substances 0.000 claims 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 1
- 235000013769 triethyl citrate Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607726P | 2012-03-07 | 2012-03-07 | |
| US61/607,726 | 2012-03-07 | ||
| PCT/US2013/029291 WO2013134348A1 (en) | 2012-03-07 | 2013-03-06 | Controlled-release solid dosage forms of mesalamine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509539A JP2015509539A (ja) | 2015-03-30 |
| JP2015509539A5 true JP2015509539A5 (enExample) | 2016-03-24 |
| JP6566638B2 JP6566638B2 (ja) | 2019-08-28 |
Family
ID=47884617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561067A Expired - Fee Related JP6566638B2 (ja) | 2012-03-07 | 2013-03-06 | メサラミンの放出制御固形製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10071058B2 (enExample) |
| EP (1) | EP2822542A1 (enExample) |
| JP (1) | JP6566638B2 (enExample) |
| AU (1) | AU2013229990B2 (enExample) |
| CA (1) | CA2866276A1 (enExample) |
| WO (1) | WO2013134348A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
| WO2017046369A1 (en) * | 2015-09-16 | 2017-03-23 | Centre National De La Recherche Scientifique (Cnrs) | Gelling compositions for treating malignant tumours and/or preventing tumour recurrence |
| BR112018071363A2 (pt) * | 2016-04-19 | 2019-02-05 | Ferring Bv | composições farmacêuticas orais de nicotinamida |
| CA3021071A1 (en) * | 2016-04-19 | 2017-10-26 | Ferring B.V. | Oral pharmaceutical compositions of mesalazine |
| JP2018052909A (ja) * | 2016-05-16 | 2018-04-05 | 日本製紙株式会社 | 化粧用組成物 |
| EP3843706A1 (en) | 2018-08-31 | 2021-07-07 | OPKO Ireland Global Holdings, Ltd. | Vitamin d pediatric dosage forms, methods of making and using |
| US20210236519A1 (en) * | 2020-01-30 | 2021-08-05 | Atoz Pharmaceuticals Pvt Ltd | Controlled release dosage forms of 5-aminosalicylic acid and process thereof |
| US12636255B2 (en) * | 2020-10-23 | 2026-05-26 | Atoz Pharmaceuticals Pvt Ltd | Nongranulated compressed tablets of mesalamine, and process of preparation thereof |
| US11975011B2 (en) * | 2020-11-03 | 2024-05-07 | Atoz Pharmaceuticals Pvt Ltd | Matrix mesalamine extended release minitablets and its process thereof |
| JP2025504173A (ja) * | 2022-02-04 | 2025-02-06 | インタクト セラピューティクス， インコーポレイテッド | メサラミン薬学的製剤およびその使用法 |
| WO2026146131A1 (en) | 2024-12-30 | 2026-07-09 | Faes Farma, S.A. | Mesalazine microparticles |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| ITMI991316A1 (it) * | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
| AR034813A1 (es) * | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| SE0102887D0 (sv) * | 2001-08-29 | 2001-08-29 | Astrazeneca Ab | New formulation |
| CN100506234C (zh) * | 2001-10-15 | 2009-07-01 | 凡林有限公司 | 用于治疗溃疡性结肠炎和克罗恩病的含有5-氨基水杨酸的药物组合物的制备方法 |
| US8916546B2 (en) * | 2003-08-29 | 2014-12-23 | Therapeutic Research Llc | Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| US7737133B2 (en) * | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
| EP1547601A1 (en) * | 2003-12-23 | 2005-06-29 | Ferring B.V. | Coating method |
| US20090017110A1 (en) * | 2005-05-31 | 2009-01-15 | Capricorn Pharma Inc. | Modified release formulations of anti-irritability drugs |
| US20070196491A1 (en) * | 2006-01-27 | 2007-08-23 | Eurand, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| EP2392321A1 (en) * | 2007-06-13 | 2011-12-07 | Jay Pravda | Combined composition for rectal administration for the treatment of inflammatory bowel disease |
| CA2739465C (en) * | 2008-10-03 | 2017-01-31 | Dr. Falk Pharma Gmbh | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
| JP2012518655A (ja) * | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | プロトンポンプ阻害剤を含む制御放出組成物 |
| WO2011045775A1 (en) * | 2009-10-16 | 2011-04-21 | Ranbaxy Laboratories Limited | A delayed release pharmaceutical composition of mesalamine |
| WO2012162492A1 (en) * | 2011-05-24 | 2012-11-29 | Teva Pharmaceutical Industries Ltd. | Compressed core comprising organic acids for a pharmaceutical composition |
-
2013
- 2013-03-06 EP EP13709723.4A patent/EP2822542A1/en not_active Withdrawn
- 2013-03-06 US US14/383,462 patent/US10071058B2/en active Active
- 2013-03-06 AU AU2013229990A patent/AU2013229990B2/en not_active Ceased
- 2013-03-06 JP JP2014561067A patent/JP6566638B2/ja not_active Expired - Fee Related
- 2013-03-06 WO PCT/US2013/029291 patent/WO2013134348A1/en not_active Ceased
- 2013-03-06 CA CA2866276A patent/CA2866276A1/en not_active Abandoned
-
2018
- 2018-08-31 US US16/119,362 patent/US10555907B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016528302A5 (enExample) | ||
| JP2017537168A5 (enExample) | ||
| JP2017128614A5 (enExample) | ||
| JP2013522373A5 (enExample) | ||
| IL273300B2 (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| US20210220281A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| JP2013512919A5 (enExample) | ||
| EP2841061A1 (en) | Methods for treating cardiovascular disorder | |
| PH12014502609B1 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug | |
| HRP20191072T1 (hr) | Farmaceutski pripravak s produljenim otpuštanjem trimetazidina | |
| JP2015508082A5 (enExample) | ||
| JP2020525436A5 (enExample) | ||
| JP2015514739A5 (enExample) | ||
| IL321388A (en) | Deferiprone extended-release tablets and methods of using them | |
| WO2017042835A1 (en) | Oral pharmaceutical dosage forms of budesonide | |
| JP2016527237A5 (enExample) | ||
| JP2015533174A5 (enExample) | ||
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| JP2017520619A5 (enExample) | ||
| RU2016115985A (ru) | Лактоферрин для лечения ibd, вызванного бактериальной инвазией | |
| JP2016512493A5 (enExample) | ||
| AU2017252407A1 (en) | Oral pharmaceutical compositions of nicotinamide | |
| WO2015085739A1 (zh) | 一种多层固体药物剂型 | |
| WO2020112060A1 (en) | A composition comprising dimethyl fumarate | |
| JP2017019880A5 (enExample) |